글로벌 아드레노백질영양증 치료 시장 - 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력 글로벌 아드레노백질영양증 치료 시장

아드레노백질영양증 치료 시장은 2022년에서 2029년의 예측 기간 동안 10.25%의 시장 성장을 목격할 것으로 예상됩니다. Data Bridge Market Research의 아드레노백질영양증 치료 시장 보고서는 예측 기간 내내 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다. 전 세계적으로 만성 질환의 유병률이 증가함에 따라 아드레노백질영양증 치료 시장 성장이 가속화되고 있습니다.

아드레노백질장애는 뇌에 장쇄 지방산(VLCFA)이 축적되는 희귀 유전적 질환을 말합니다. ALD는 X 염색체의 ABCD1 유전자 돌연변이로 인해 발생합니다. 아드레노백질장애에는 아드레노미엘로파시, 소아 뇌 ALD, 애디슨병 등 세 가지 유형이 있습니다. 소아 뇌 ALD는 3~10세 사이의 어린이에게 빠르게 진행되는 것으로 알려져 있습니다.

전 세계적으로 아드레노백질이영양증을 앓고 있는 영아의 수가 증가하는 것은 아드레노백질이영양증 치료 시장 성장을 견인하는 주요 요인 중 하나입니다. 유전자 돌연변이로 인한 합병증을 치료하기 위한 표적 약물에 대한 수요 증가와 새로운 개입을 개발하기 위한 연구자에 대한 재정 지원 증가는 시장 성장을 가속화합니다. ALD를 치료하기 위한 제조업체 간 합병 및 협업의 급증과 연구 개발 프로그램의 수 증가는 시장에 더 많은 영향을 미칩니다. 또한 기술 개발, 의료비 지출 급증 , 유전적 질환 유병률 증가 및 인구 증가는 아드레노백질이영양증 치료 시장에 긍정적인 영향을 미칩니다. 나아가 환자 접근성을 높이고 2022년에서 2029년의 예측 기간 동안 시장 참여자에게 수익성 있는 기회를 확대합니다.

On the other hand, side-effects associated with stem cell therapy and corticosteroid replacement therapy are expected to obstruct the market growth. The stringent regulations are projected to challenge the adrenoleukodystrophy treatment market in the forecast period of 2022-2029.

This adrenoleukodystrophy treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info adrenoleukodystrophy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Adrenoleukodystrophy Treatment Market Scope and Market Size

The adrenoleukodystrophy treatment market is segmented on the basis of types, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of types, the adrenoleukodystrophy treatment market is segmented into childhood cerebral Adrenoleukodystrophy (ccALD), adrenomyelopathy, Addison’s disease and others.
• The treatment segment for adrenoleukodystrophy treatment market includes medication, gene therapy, bone marrow transplantation and others.
• On the basis of route of administration, adrenoleukodystrophy treatment market is segmented into oral and parenterals.
• Based on end-user, the adrenoleukodystrophy treatment market is segmented into hospitals, homecare, specialty clinics and others
• Adrenoleukodystrophy treatment market has also been segmented based on the distribution channel into hospital, pharmacy, online pharmacy, retail pharmacy and others.

Adrenoleukodystrophy Treatment Market Country Level Analysis

The adrenoleukodystrophy treatment market is analyzed and market size information is provided by country, types, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global adrenoleukodystrophy treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the adrenoleukodystrophy treatment market due to the well-established healthcare infrastructure and presence of key market players within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the rise in awareness about rare diseases in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The adrenoleukodystrophy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Adrenoleukodystrophy Treatment Market Share Analysis

The adrenoleukodystrophy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related adrenoleukodystrophy treatment market.

부신백질이영양증 치료 시장 보고서에서 활동하는 주요 기업으로는 bluebird bio, Inc., Orpheris, Inc., MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer Inc., Amgen Inc., AstraZeneca, Abbott, agtc, ReceptoPharm, Inc., The Myelin Project, SOM Biotech SL, Viking Therapeutics, Nutra Pharma Corporation, Genetix Biotech Asia Pvt. Ltd., Magenta Therapeutics, NeuroVia, Inc., Novartis AG, CELGENE CORPORATION, Jazz Pharmaceuticals, Inc., Sanofi 등이 있습니다.

SKU-50726